The abstract is read at the publisher; the summary is JClub's.
In 301 patients with FDG-avid rhabdomyosarcoma, PET detected bone marrow metastases with 98% sensitivity and 90% specificity versus BMAB, enabling omission when PET is negative.
- Why it matters: Bone marrow aspirates/biopsies are a staging gold standard in rhabdomyosarcoma, but they are invasive; the study tests whether FDG PET can safely replace sampling.
- What they did: Europe and North America records were reviewed for FDG PET/CT or FDG PET/MRI and BMAB results, with images re-reviewed when PET suggested uptake or when marrow samples showed tumor cells.
- The result: Bone marrow metastases were found by PET and BMAB in 54 patients, by PET only in 24, and by BMAB only in one; PET-negative marrow had concordant absence in 222/301, supporting omitting sampling.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.